CA2848724A1 - Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer - Google Patents

Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer Download PDF

Info

Publication number
CA2848724A1
CA2848724A1 CA2848724A CA2848724A CA2848724A1 CA 2848724 A1 CA2848724 A1 CA 2848724A1 CA 2848724 A CA2848724 A CA 2848724A CA 2848724 A CA2848724 A CA 2848724A CA 2848724 A1 CA2848724 A1 CA 2848724A1
Authority
CA
Canada
Prior art keywords
nhc
amino
compound
phenyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2848724A
Other languages
English (en)
French (fr)
Inventor
Arthur Decillis
Rodrigo RUIZ SOTO
Gary Thomas Emmons
Joanne LAGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Exelixis Inc
Original Assignee
Sanofi SA
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA, Exelixis Inc filed Critical Sanofi SA
Publication of CA2848724A1 publication Critical patent/CA2848724A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2848724A 2011-09-14 2012-09-14 Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer Abandoned CA2848724A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161534836P 2011-09-14 2011-09-14
US61/534,836 2011-09-14
US201161543529P 2011-10-05 2011-10-05
US61/543,529 2011-10-05
US201161562670P 2011-11-22 2011-11-22
US61/562,670 2011-11-22
PCT/US2012/055387 WO2013040337A1 (en) 2011-09-14 2012-09-14 Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA2848724A1 true CA2848724A1 (en) 2013-03-21

Family

ID=46940622

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2848724A Abandoned CA2848724A1 (en) 2011-09-14 2012-09-14 Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer

Country Status (10)

Country Link
EP (1) EP2755654A1 (cg-RX-API-DMAC7.html)
KR (1) KR20140077911A (cg-RX-API-DMAC7.html)
AU (1) AU2012308414A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014005858A2 (cg-RX-API-DMAC7.html)
CA (1) CA2848724A1 (cg-RX-API-DMAC7.html)
IL (1) IL231448A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN02671A (cg-RX-API-DMAC7.html)
TW (1) TW201325592A (cg-RX-API-DMAC7.html)
UY (1) UY34339A (cg-RX-API-DMAC7.html)
WO (1) WO2013040337A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113754565B (zh) * 2021-11-09 2022-02-22 南京威凯尔生物医药科技有限公司 一种连续流微反应器中制备沙库巴曲中间体的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
HRP20130902T1 (hr) 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
WO2007044481A1 (en) 2005-10-07 2007-04-19 Basf Corporation Clearcoat coating composition
HRP20140975T1 (hr) * 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
UA98141C2 (ru) * 2007-04-11 2012-04-25 Экселиксис, Инк. Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
WO2010146391A1 (en) * 2009-06-15 2010-12-23 Generics [Uk] Limited Regioselective synthesis of letrozole
WO2012065057A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use

Also Published As

Publication number Publication date
WO2013040337A9 (en) 2014-04-03
EP2755654A1 (en) 2014-07-23
WO2013040337A1 (en) 2013-03-21
IN2014CN02671A (cg-RX-API-DMAC7.html) 2015-07-03
TW201325592A (zh) 2013-07-01
AU2012308414A1 (en) 2014-05-01
IL231448A0 (en) 2014-04-30
BR112014005858A2 (pt) 2017-06-13
KR20140077911A (ko) 2014-06-24
UY34339A (es) 2013-04-30

Similar Documents

Publication Publication Date Title
AU2008236562B2 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
EP3601281B1 (en) CRYSTALLINE FORMS OF 4-(1-(1,1-DI(PYRIDIN-2-YL)ETHYL)-6-(3,5-DIMETHYLISOXAZOL-4-YL)-1H-
PYRROLO[3,2-B]PYRIDIN-3-YL)BENZOIC ACID THAT INHIBITS BROMODOMAIN
TW202521120A (zh) 藥物組合物及其應用
CN103874494A (zh) 使用pi3k/mtor的吡啶并嘧啶酮抑制剂与苯达莫司汀和/或利妥昔单抗治疗恶性血液病的组合疗法
EP2142544B1 (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
JP2010523677A (ja) 癌の治療のためのPI3Kα阻害剤としてのピリド[2,3−D]ピリミジン−7−オン
WO2012149308A1 (en) Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor
CN105050602A (zh) 作为pi3激酶抑制剂的吡啶化合物
KR20140077911A (ko) 암의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제
WO2013056067A1 (en) Compounds for use in the treatment of basal cell carcinoma
HK1139941B (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
WO2024255883A1 (zh) Akt抑制剂在制备预防或治疗乳腺癌药物中的用途

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150915